Pasithea Therapeutics Corp. KTTA 深 滬
已收盤 02-06 16:00:00 美东时间
0.725
-0.037
-4.82%
華盛通- 最 高0.7834
- 今 開0.7544
- 成交量 32.72万股
- 最 低 0.7144
- 昨 收 0.7617
- 總市值 1674.10万
- 52周最高 3.79
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 0.281
- 委 比 -63.32%
- 總股本 2309.11万
- 歷史最高 170.00
- 量 比 2.48
- 振 幅 9.06%
- 歷史最低 0.281
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization
The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On Januar...
01-29 05:58
Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients
Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the
01-13 20:08
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Pasithea Therapeutics Corp. provided updates on its clinical trials for PAS-004, a next-generation MEK inhibitor for NF1-associated plexiform neurofibromas and advanced cancers. In the Phase 1/1b trial for NF1-PN, 12 patients were enrolled in the first four dose cohorts, with data expected in late 2026. The Phase 1 trial for advanced cancers plans to present long-term follow-up data from Cohorts 4 to 8 in Q2 2026. CEO Dr. Tiago Reis Marques highl...
01-13 12:01
Pasithea Therapeutics Regains Nasdaq Compliance
Pasithea Therapeutics Corp ( ($KTTA) ) has shared an announcement. Pasithea The...
2025-12-15 21:55
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
HC Wainwright & Co. Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3
HC Wainwright & Co. analyst Sara Nik initiates coverage on Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $3.
2025-12-08 20:44
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Pasithea Therapeutics Announces Pricing Of Public Offering Of 80M Shares At Offering Price Of $0.75/Shr Of Common Stock
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital
2025-11-28 22:25
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after ...
2025-11-28 17:49
Pasithea Therapeutics Announces Phase 1 Data From Its Ongoing First-In-Human Trial Evaluating PAS-004; Partial Response Observed In A MEK-Rechallenge 3rd-line Melanoma Patient With Braf V600e Mutation Who Remains On Trial For More Than 11 Months; PAS-004 Has Been Well-Tolerated With All Treatment
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis
2025-11-21 05:06
